Soligenix Announces Positive Results for Psoriasis Trial Extension

Soligenix Inc. (NASDAQ:SNGX) announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis. The gel formulation was well-tolerated by all patients, with improvements in Investigator Global Assessment, Psoriasis Activity and Severity Index, and other clinical measures. One patient achieved a disease status of "Almost Clear," exceeding 50% improvement in PASI score. Soligneix stock is down 21.05% at $1.21.